ERBB2 and non-small cell lung carcinoma: In the meantime, immunotherapy has been used in real-world scenarios for patients with HER2-alterated (MUT or AMP) NSCLC, in pretreated patients and then in first-line therapy associated with chemotherapy (data derive from retrospective studies) [101,102,103,104,105,106,107,108,109,110,111,112].